You are viewing the site in preview mode

Skip to main content

Table 2 The result of meta-regression

From: Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis

Variables

outcome

beta with 95% CI

Standard error

P-value

Age

PTLD

0.21 (− 0.35, 0.78)

0.29

0.461

 

EBV viremia

0.28 (− 0.19, 0.77)

0.24

0.244

Transplant type

PTLD

0.17 (0.05, 0.29)

0.06

0.003

 

EBV viremia

 − 0.04 (− 0.25, 0.17)

0.10

0.708

Serostatus

PTLD

 − 0.04 (− 1.15, 1.05)

0.56

0.930

 

EBV viremia

0.04 (− 0.57, 0.66)

0.31

0.894

Antiviral agent

PTLD

0.02 (− 0.08, 0.14)

0.05

0.648

 

EBV viremia

0.04 (− 0.23, 0.13)

0.09

0.606

Intervention duration

PTLD

 − 0.09 (− 0.44, 0.24)

0.17

0.582

Induction immunosuppression

PTLD

0.16 (0.00, 0.31)

0.08

0.045

 

EBV viremia

0.14 (− 0.11, 0.40)

0.13

0.282

Maintenance immunosuppression

PTLD

 − 0.53 (− 0.97, −0.09)

0.22

0.017

 

EBV viremia

 − 0.23 (− 0.76, 0.29)

0.27

0.386

Decade of publication

PTLD

 − 0.01 (− 0.43, 0.41)

0.21

0.958

  1. EBV Epstein-Barr virus, PTLD Post-transplant lymphoproliferative disorders